Compare abrdn Income Credit Strategies Fund (ACP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Novo Nordisk A/S — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Novo Nordisk A/S trades at $48.92 (market cap $220.20B). The key difference: Novo Nordisk A/S is far larger — about 335.6× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | NVO | |
|---|---|---|
Market Cap | $656.21M | $220.20B |
Sector | Financials | Health |
52-Week High | $5.98 | $71.70 |
52-Week Low | $5.01 | $35.29 |
Dividend Yield | 17.78% | 3.63% |
Enterprise Value | — | $239.16B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
